Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Cash flows from operating activities
Net loss	$ (20,737)	$ (28,796)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	12	15
Stock-based compensation expense	2,396	2,474
Amortization of premiums and accretion of discounts on marketable securities, net	25	(588)
Change in fair value of embedded derivatives	(460)	(190)
Amortization of right-of-use asset	34	30
Realized gain on marketable securities	(6)	(3)
Noncash interest expense	346	299
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	691	950
Other long-term assets	0	16
Accounts payable	1,047	(4,592)
Accrued clinical trial expenses	(2,433)	(3,796)
Accrued expenses and other liabilities	(5,043)	60
Net cash used in operating activities	(24,128)	(34,121)
Cash flows from investing activities
Purchases of marketable securities	(40,823)	(35,048)
Proceeds from maturities and sales of marketable securities	27,016	63,816
Purchases of property and equipment	0	(79)
Net cash (used in) provided by investing activities	(13,807)	28,689
Cash flows from financing activities
Proceeds from private placement, net of offering costs	35,746	0
Proceeds from exercise of stock options	145	37
Repurchase of common shares to pay employee withholding taxes	(149)	(73)
Net cash provided by (used in) financing activities	35,742	(36)
Net change in cash and cash equivalents and restricted cash	(2,193)	(5,468)
Cash and cash equivalents and restricted cash at the beginning of the period	54,220	35,859
Cash and cash equivalents and restricted cash at the end of the period	52,027	30,391
Supplemental disclosure of cash flow information
Cash paid for income taxes	0	0
Cash paid for interest	723	724
Supplemental disclosure of noncash financing activities
Offering costs included in accounts payable	54	0
Offering costs included in accrued expenses and other current liabilities	$ 239	$ 0